(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

ANTICORPOS ANTI-BTN3A E SEU USO NO TRATAMENTO DE CÂNCER OU DISTÚRBIOS INFECCIOSOS

Em ExigênciaInvention PatentPCT · EP2019070693

Application data

Number

112021001776

Type

Invention Patent

Filing

07/31/2019

Publication

05/04/2021

PCT

EP2019070693

Progress at the INPI

Technical opinion to answer
  1. Filing07/31/19
  2. Publication05/04/21
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 03/03/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS

FR

IMCHECK THERAPEUTICS SAS

FR

INSTITUT JEAN PAOLI & IRENE CALMETTES

FR

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

FR

U. M. (pessoa física)

FR

See this company's full portfolio

Inventors

A. T. (pessoa física)

US

A. G. (pessoa física)

FR

C. P. (pessoa física)

FR

D. O. (pessoa física)

FR

Technical data

Priority claims

EP

18306050.8 · 08/01/2018

EP

19153992.3 · 01/28/2019

Abstract

ANTICORPOS ANTI-BTN3A E SEU USO NO TRATAMENTO DE CÂNCER OU DISTÚRBIOS INFECCIOSOS. A presente invenção se refere a anticorpos humanizados que se ligam especificamente ao BTN3A humano e seu uso no tratamento de câncer e distúrbios infecciosos.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

03/03/2026

RPI 2878

Notificação de entrada na fase nacional - PCT

#1.3

05/04/2021

RPI 2626

Alteração de dados cadastrais

#1.1

02/09/2021

RPI 2614

Related

From the same holder

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.